



US Patent granted for Amal Therapeutics' novel cancer vaccine technology platform

GENEVA, December 1, 2015 – Amal Therapeutics SA ("Amal"), a biotechnology company developing active immunotherapies, announced the issuance on November 17, 2015 of the US Patent number 9,187,534 entitled "MULTI-EPITOPIC VACCINE" by the US Patent and Trademark Office (USPTO). This patent covers Amal's multi-epitopic vaccine technology platform and its use as immunotherapy for the treatment of cancers.

This proprietary technology is applicable for the development of indication-tailored vaccines incorporating the University of Geneva exclusively licensed vector family. The versatile and flexible recombinant protein-based technology platform gives Amal's vaccines the unique property to simultaneously activate killer and helper T cells; two subsets essential for potent anti-cancer immunity.

"The issuance of this patent is a significant step in Amal Therapeutics development plans and the recognition of the potential of Amal's novel technology platform. This broadens our intellectual property position and establishes a solid foundation for future Amal's R&D portfolio" said Madiha Derouazi, Amal Therapeutics CEO.

About Amal Therapeutics SA

Amal Therapeutics SA is a privately held Swiss/German biotech start-up company and spin-off from the University of Geneva. Amal Therapeutics was incorporated in September 2012. Amal uses its proprietary technology platform, to develop and progress therapeutic vaccines in oncology. www.amaltherapeutics.com, contact@amaltherapeutics.com